Skip to content
Waklert

Waklert

Quality products
24/7 Support
Fast delivery
Delivery from 4 days
Active ingredient Armodafinil

Free delivery on orders from £ 166.00, free express delivery from £ 249.00

Waklert acts on the central nervous system to support sustained alertness, with a longer-lasting profile than modafinil. It is intended for adults whose excessive daytime sleepiness is linked to narcolepsy, obstructive sleep apnoea, or shift-work sleep disorder.

Overview

Armodafinil, the active ingredient associated with Waklert, is a wakefulness-promoting agent for adults with excessive daytime sleepiness linked to conditions such as narcolepsy, obstructive sleep apnoea, or shift-work sleep disorder.

Directions for use

Waklert is provided as oral tablets. The appropriate strength depends on the sleep disorder being treated, the severity of daytime sleepiness, other medicines, liver function, cardiovascular history, and the person’s response during the first weeks of treatment.

Clinical prescribing usually follows these principles:

  • Start with the strength selected for the diagnosed sleep disorder.
  • Take it at the same time on each treatment day.
  • Avoid changing the dose because of a single unusually sleepy or alert day.
  • Do not take an extra tablet after poor sleep.
  • Do not use Waklert to extend waking hours for study, social activity, or work beyond the prescribed purpose.
  • If a dose is missed, take it only when there is enough time before bedtime to avoid insomnia; a missed dose should not be doubled.
Keep a simple record of sleep time, dosing time, alertness, headaches, anxiety, and blood pressure when treatment begins. This gives the prescriber useful information without encouraging self-adjustment.

Formulation

Waklert is supplied as tablets containing armodafinil, the R-enantiomer of modafinil. It belongs to the wakefulness-promoting class and acts within the central nervous system rather than functioning as a conventional stimulant such as amphetamine.

Mechanism of action

Armodafinil influences several neurotransmitter systems. Its best-established action involves inhibition of the dopamine transporter, which reduces dopamine reuptake and increases dopamine signalling in selected brain regions. Effects on noradrenaline, histamine, glutamate, and orexin pathways also contribute to wakefulness, although the complete mechanism remains under investigation.[1]

Role of Armodafinil in Neurotransmitter Regulation

Armodafinil is a single stereoisomer of modafinil. The R-enantiomer remains in the body for longer than the S-enantiomer, producing a more sustained pharmacokinetic profile than racemic modafinil.

Dopamine signalling is relevant to alertness, motivation, and attention. Waklert does not simply “release excess dopamine” in a generalised way. It primarily reduces dopamine transporter activity, allowing dopamine to remain available for longer at certain synapses. This distinction matters because the clinical effect is wakefulness, not a guaranteed improvement in mood, memory, or productivity.

Armodafinil also has a lower potential for widespread cardiovascular stimulation than traditional amphetamine-type stimulants, though increased blood pressure, palpitations, anxiety, and agitation can still occur. The MHRA expects medicines affecting alertness and the central nervous system to be used with attention to individual response, psychiatric history, and other medicines.

Therapeutic indications

The medicine is used to reduce excessive sleepiness associated with:

  • Narcolepsy
  • Obstructive sleep apnoea when residual daytime sleepiness persists despite appropriate primary treatment
  • Shift-work sleep disorder

Common mistakes

Several practical errors can reduce benefit or increase adverse effects:

  • Taking the tablet late in the afternoon.
  • Doubling the next dose after a missed tablet.
  • Adding large amounts of caffeine to overcome residual sleepiness.
  • Using Waklert after an entire night without sleep.
  • Stopping prescribed sleep-apnoea treatment because daytime alertness improves.
  • Assuming that a higher strength will correct poor sleep habits.
  • Ignoring new anxiety, irritability, palpitations, or a spreading rash.
  • Forgetting to mention hormonal contraception to the prescriber.
  • Taking supplements marketed for concentration without checking their stimulant content.
  • Crushing or splitting tablets without confirmation that the particular formulation permits it.

One subtle mistake is judging treatment only by the first few hours. Armodafinil can have a delayed peak and a prolonged elimination phase, so early-day alertness does not show the full exposure. Another is taking the medicine on a day when driving is planned without knowing how it affects concentration, reaction time, and visual attention.

Reasons not to use it

Waklert is contraindicated in people with a serious allergic reaction to armodafinil, modafinil, or an excipient in the tablet. Caution is required with a history of severe medicine-related rash because rare but serious skin reactions can occur.

Clinical situations requiring assessment include:

  • Uncontrolled hypertension
  • Significant heart disease, arrhythmia, or chest pain
  • Previous psychosis, mania, or severe depression
  • Bipolar disorder
  • Liver impairment
  • A history of substance misuse
  • Pregnancy or breastfeeding
  • Use of hormonal contraception
  • Treatment with MAOIs, linezolid, ritonavir, anticonvulsants, or anticoagulants

Isocarboxazid is a monoamine oxidase inhibitor, and linezolid has monoamine oxidase-inhibiting activity. Combining either with a wakefulness-promoting medicine may increase the risk of dangerous blood-pressure changes, agitation, or other central nervous system effects. Ritonavir can alter armodafinil exposure through enzyme effects. Cobimetinib also requires a formal interaction review because changes in drug metabolism may affect treatment safety.

The FDA prescribing information identifies clinically relevant interactions involving hormonal contraceptives, cyclosporine, warfarin, certain anticonvulsants, and other medicines metabolised through hepatic enzyme pathways.[2]

When this is not for you

This may not be suitable for you if you have had a serious allergic reaction to armodafinil or modafinil, or if a medicine has previously caused you to develop a severe rash. Speak with the prescriber before use if you have uncontrolled blood pressure, heart disease, an irregular heartbeat, chest pain, liver problems, bipolar disorder, psychosis, severe depression, or a history of substance misuse.

Tell the prescriber if you are pregnant or breastfeeding, use hormonal contraception, or take medicines such as MAOIs, linezolid, ritonavir, anticonvulsants, or anticoagulants. Armodafinil can make hormonal contraception less reliable. Do not combine Waklert with recreational stimulants, high quantities of caffeine, or unregulated “nootropic” products.

Tell the prescriber about contraceptive tablets, implants, patches, injections, and hormonal rings. Armodafinil can make hormonal contraception less reliable even when no side effect is noticeable.

Unwanted effects

Common adverse effects include:

  • Headache
  • Dry mouth
  • Nausea
  • Reduced appetite
  • Anxiety or nervousness
  • Dizziness
  • Insomnia
  • Palpitations
  • Increased blood pressure

Headache is often reported during the early phase of treatment. Adequate fluid intake, regular meals, and avoiding unnecessary caffeine may help, though a persistent or severe headache requires medical assessment.

Dry mouth can make swallowing uncomfortable and may worsen dental problems when it persists. Sugar-free gum or frequent small sips of water can help. New mouth ulcers, facial swelling, or difficulty breathing need urgent attention because they may indicate an allergic reaction.

Insomnia is more likely after late dosing, additional caffeine, irregular sleep, or using Waklert to compensate for repeated sleep restriction. A person who feels unusually restless, euphoric, impulsive, or agitated needs prompt clinical review, since armodafinil can aggravate psychiatric symptoms in susceptible individuals.

Serious symptoms requiring urgent medical attention include:

  • Chest pain, fainting, or severe shortness of breath
  • A fast or irregular heartbeat that does not settle
  • Severe agitation, hallucinations, mania, or suicidal thoughts
  • Facial or tongue swelling
  • Blistering, peeling, or widespread rash
  • Fever with rash, mouth sores, or eye irritation
  • Severe allergic symptoms

Comparison

Comparison of Waklert and Modafinil-Based Treatment

Treatment Active substance and profile Practical distinction
Waklert Armodafinil, the R-enantiomer of modafinil More sustained exposure may support wakefulness later in the day
Modafinil-based treatment Modafinil, a mixture of R- and S-enantiomers Established wakefulness treatment with a different concentration profile
Traditional stimulants Agents such as amphetamine derivatives Greater stimulant-type effects and a different misuse and cardiovascular profile

Armodafinil and modafinil both affect dopamine transporters and other wakefulness pathways. Neither should be described as a simple dopamine-releasing medicine. Differences in stereochemistry influence absorption, elimination, and the concentration pattern over time.

A person who changes from modafinil to armodafinil should not assume that the same numerical dose produces an identical clinical effect. The switch requires a planned regimen, especially when insomnia, anxiety, blood-pressure elevation, or other medicines are present.

What doctors say

In clinical practice, doctors usually judge Waklert by daytime function rather than by a feeling of stimulation. A useful response means fewer unintended sleep episodes and improved ability to remain awake during ordinary activities.

Sleep-apnoea treatment deserves special attention. Waklert may reduce residual sleepiness, but it does not treat airway collapse. Prescribed positive-airway-pressure treatment must continue when indicated, and persistent sleepiness should prompt a review of sleep duration, treatment adherence, mask problems, and other sedating medicines.

Doctors also ask about sleep timing, caffeine, alcohol, depression, anxiety, and shift patterns. These factors can make armodafinil appear ineffective or can amplify unwanted effects.

The WHO describes sleep disorders as conditions requiring assessment of symptoms, function, and contributing health factors rather than treatment based on tiredness alone.[3] That approach is relevant because excessive sleepiness can arise from sleep deprivation, sedating medicines, depression, anaemia, thyroid disease, or untreated sleep apnoea.

Comparison

Comparison table: Narcolepsy

What customers often ask

Is Waklert suitable during pregnancy or breastfeeding?

Armodafinil requires a specific pregnancy and breastfeeding assessment. The FDA's 2015 prescribing information warns that armodafinil may reduce the reliability of hormonal contraceptives and that pregnancy exposure requires discussion of potential risks. The MHRA also expects medicine decisions during pregnancy to consider the condition being treated, alternatives, and maternal wellbeing. Breastfeeding should be reviewed individually because the medicine’s presence in breast milk and its possible effects on an infant require clinical judgement.

Can Waklert be used before driving, concentration, or machinery work?

Waklert is intended to reduce excessive sleepiness, but it does not guarantee normal reaction time or judgement. The MHRA advises caution with medicines that affect the central nervous system, especially when treatment has just started or the dose has changed. The FDA label dated 2015 also advises against driving or operating machinery when armodafinil causes dizziness, anxiety, overstimulation, sleepiness, or visual impairment. Do not drive or operate machinery if you feel dizzy, anxious, overstimulated, sleepy, or visually impaired. A person whose sleep disorder remains uncontrolled may still be unsafe to drive despite taking armodafinil.

Can Waklert be combined with antidepressants or other medicines?

The combination requires a medicine review rather than a general yes-or-no answer. Isocarboxazid and linezolid can create a serious interaction risk because of monoamine oxidase activity, while ritonavir and other enzyme-modifying medicines can change armodafinil exposure. The 2018 EMA approach to centrally acting medicines places emphasis on checking the complete treatment list, including anticoagulants, anticonvulsants, hormonal contraceptives, and supplements.[4] Do not add stimulant-containing supplements or high-dose caffeine without checking the planned combination.

Which diet, exercise, or habits support the result?

A stable sleep schedule, adequate nightly sleep, treatment adherence for sleep apnoea, and moderate caffeine use can support the intended result. Alcohol may worsen sleep quality and can make daytime sleepiness harder to assess. Exercise can support sleep and alertness when it does not replace needed rest or take place so late that it disrupts sleep. A regular breakfast or light meal may help people who experience nausea, while heavy caffeine use can intensify nervousness and palpitations. The WHO's 2022 health guidance also supports addressing sleep habits and contributing health factors alongside treatment.

What is the best time of day to take Waklert?

Waklert is generally taken in the morning when prescribed for daytime sleepiness. Shift-work schedules may require a different agreed timing, linked to the planned waking period rather than a standard clock time. Taking it late can prolong alertness into the intended sleep period because armodafinil has a long elimination half-life. Do not move the dose repeatedly from day to day without discussing the pattern with the prescriber. The FDA's 2015 prescribing information supports morning dosing for daytime sleepiness.

Which symptoms mean stopping Waklert and seeking urgent medical help?

Urgent assessment is needed for facial or tongue swelling, breathing difficulty, widespread blistering or peeling rash, mouth or eye sores, chest pain, fainting, severe palpitations, hallucinations, mania, or suicidal thoughts. Severe rash with fever is a medical emergency because rare serious skin reactions can begin with flu-like symptoms. Stop and seek urgent advice if these symptoms develop rather than taking another dose while waiting for them to settle. Headache or dry mouth alone is usually less urgent, but persistent or severe symptoms still require a treatment review. The FDA's 2015 prescribing information identifies severe rash and serious psychiatric symptoms as reasons for urgent medical assessment.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

How Buyers Rate Waklert

3.6
Based on 4 reviews
Tom, 48
Nottingham
Several weeks
Verified
Rating: 4 out of 5

Nottingham, reported taking his prescribed morning tablet at the prescribed dose for several weeks. He said that unplanned nodding off during desk work became less frequent, although the first days brought a dry mouth and a mild headache. Drinking more water helped, while an extra coffee made him feel tense.

6 Oct 2026
Gareth L., 53
Middlesbrough
Several weeks
Verified
Rating: 3.5 out of 5

Middlesbrough, used Waklert at the prescribed dose for several weeks during treatment for persistent daytime sleepiness linked to a night-shift pattern. He felt more alert during the first half of his shift, but late dosing caused poor sleep after getting home. Moving the dose earlier within his agreed schedule improved that problem.

16 Oct 2026
Luke, 63
Bradford
Several weeks
Verified
Rating: 4 out of 5

Bradford, found that daytime alertness improved after several weeks at the prescribed dose, when treatment was reviewed alongside his sleep-apnoea care. He still felt tired after short nights and initially expected the tablet to compensate for lost sleep. His main complaint was intermittent nausea during the first week.

23 Oct 2026
Simon V., 66
Bournemouth
Several weeks
Verified
Rating: 3 out of 5

Bournemouth, stopped treatment after several weeks at the prescribed dose, when he developed marked palpitations and anxiety. The symptoms settled after medical review, and he said the experience showed why changing the dose independently was unhelpful.

3 Nov 2026

Sources

  1. U.S. Food and Drug Administration (2015). Nuvigil (armodafinil) Prescribing Information
  2. U.S. Food and Drug Administration (2015). Nuvigil Pregnancy, Contraception, and Drug Interaction Information
  3. World Health Organization (2022). World Mental Health Report: Transforming Mental Health for All
  4. European Medicines Agency (2018). Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Narcolepsy
Get our free app Shop faster and track your orders 3.9 · 433 reviews Install